Altius Investech on API Holdings - Message Received

Blog Disclaimer  ; Message as Received. 

Please Recheck all facts

-----------------

MESSAGE

 

 

API Holdings: From Losses to Profitability — FY26 Turnaround Story

We present API Holdings Ltd. — a leading digital healthcare platform operating across B2B pharma distribution (Ascent & Aknamed), B2C consumer platform (PharmEasy), and diagnostics (Thyrocare), creating a fully integrated healthcare ecosystem across India.   Business Overview Diversified platform across supply chain, consumer & diagnostics B2B: Supplies medicines to chemists, hospitals & institutions B2C:PharmEasy enables online medicine delivery & healthcare access Diagnostics:Thyrocare offers nationwide testing with strong margins End-to-end presence across manufacturers → hospitals → consumers    9MFY26 Financial Turnaround Clear shift from losses to profitability Revenue at ₹5,095 Cr, up +15% YoY  EBITDA turned positive at ₹29 Cr vs losses earlier Finance cost reduced to ₹340 Cr (-14% YoY) PBT losses narrowed by 38% YoY   Thyrocare — Core Driver of Turnaround High-margin diagnostics business powering profitability Revenue: ₹605 Cr, up +21% YoY Gross margin: 73% (among highest in diagnostics) EBITDA: ₹201 Cr with 33% margin Consistent quarterly margins (32–35%) supporting group EBITDA Thyrocare is the primary cash engine enabling the group’s EBITDA turnaround   Other Segments Improving Rapidly B2B & B2C showing sharp operational recovery B2B Revenue: ₹3,043 Cr (+16% YoY); EBITDA loss reduced by 75% First EBITDA-positive quarter achieved in Q3FY26 B2C Revenue: ₹983 Cr (+18% YoY); gross margins expanded to 25% EBITDA losses narrowed to ₹34 Cr vs ₹47 Cr YoY

­ Follow us on social media to keep yourself updated!

Latest From Social Media

­ Follow Us on Linkedin ­

­ ­ ­ ­ ­

For any assistance, feel free to contact our support team at +918240614850 or support@altiusinvestech.com